Arcutis shares jump as analysts raise price targets and lift 2026 sales guidance
Arcutis Biotherapeutics saw its stock rise over 10% after Guggenheim upgraded the company to Buy and lifted its price target to $44, while Cantor Fitzgerald assigned an Overweight rating with a $48 target. The upgrades followed the release of second‑quarter results that showed a net income of $15 million and revenue of $129.86 million, a 59% year‑over‑year increase. The company also raised its full‑year 2026 product‑sales guidance to $525 million‑$540 million. Management highlighted continued growth of its Zoryve dermatology franchise and expects operating leverage to improve in 2027.
Why it matters
Guggenheim’s note says the higher target reflects growing conviction for 2027 performance, suggesting investors may price in stronger future earnings. The raised 2026 sales guidance, cited by the company, signals higher near‑term revenue expectations, which could support the stock’s upward momentum.
Key facts
- 1Guggenheim raised its price target to $44 from $38 and kept a Buy rating. finance.yahoo.com
- 2Cantor Fitzgerald gave an Overweight rating and a $48 price target. finance.yahoo.com
- 3Arcutis shares rose 12% after the Guggenheim upgrade. finance.yahoo.com
- 4Arcutis shares rose 10.65% to close at $31.89 after the analyst upgrades. insidermonkey.com
- 5Second‑quarter net income was $15 million, reversing a loss of $15.9 million a year earlier. insidermonkey.com
- 6Second‑quarter revenue was $129.86 million, up 59% from $81.5 million a year earlier. insidermonkey.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.